Regdanvimab

Regdanvimab is a monoclonal antibody medication that is used for the treatment of COVID-19. It was developed by the South Korean company Celltrion.

Etymology

The name "Regdanvimab" is derived from the words "regulation", "antiviral", and "monoclonal antibody". The "reg" in "Regdanvimab" refers to the drug's ability to regulate the immune response to the virus, the "danvi" is a reference to its antiviral properties, and the "mab" at the end of the name is a common suffix for monoclonal antibodies.

Medical Uses

Regdanvimab is used for the treatment of mild to moderate COVID-19 in adults who are at high risk of progressing to severe COVID-19. It is administered via intravenous infusion.

Mechanism of Action

Regdanvimab is a monoclonal antibody that targets the spike protein of SARS-CoV-2, the virus that causes COVID-19. By binding to the spike protein, it prevents the virus from entering human cells, thereby inhibiting viral replication.

Development and Approval

Regdanvimab was developed by the South Korean company Celltrion. In February 2021, it was granted conditional marketing authorization by the Ministry of Food and Drug Safety (MFDS) in South Korea for the treatment of high-risk patients with mild to moderate COVID-19.

See Also

• Monoclonal antibodies
• COVID-19 treatment
• Celltrion